Last updated: August 18, 2026

Examiner: BERRY, LAYLA D

Tech Center 1600 • Art Units: 1623 1673 1693

This examiner grants 66% of resolved cases

Performance Statistics

65.9%

Allow Rate

+5.9% vs TC avg

1,480

Total Applications

+8.9%

Interview Lift

1015

Avg Prosecution Days

Based on 1445 resolved cases, 2023–2026

3.9%

§101 Eligibility

19.6%

§102 Novelty

34.3%

§103 Obviousness

25.2%

§112 Clarity

App #	Title	Status	Assignee
18036732	METHODS OF OLIGONUCLEOTIDE-BASED AFFINITY CHROMATOGRAPHY	Non-Final OA	DONALDSON COMPANY, INC.
18597314	METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT	Final Rejection	Boehringer Ingelheim International GmbH
17620541	AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME	Non-Final OA	CELGENE CORPORATION

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.